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How to assess renal function in patients with a neobladder
To the Editor
Radical cystectomy and intestinal urinary diversion are standard
treatments for patients with localized muscle-invasive bladder cancer.
Although long-term survival is increasing, a decline of renal function
after urinary diversion is a well-known complication, with a prevalence
of 20–70% [1]. The reasons are multiple: ureteral obstruction, pyelo-
nephritis, reflux and factors not specific to urinary diversion (medica-
tion, chemotherapy, hypertension, diabetes mellitus). At this moment,
there is a paucity of renal outcome data. In addition, a universal defi-
nition of how to assess renal function and what can be considered as the
optimal diagnostic method is absent [1,2].
As mentioned in a systematic review evaluating renal function in
patients undergoing orthotopic bladder substitution, none of the de-
scribed equations to determine the glomerular filtration rate (GFR) has
been validated in this patient group [2]. Historically, inulin clearance is
considered as the gold-standard method for measuring GFR. However,
this procedure has several disadvantages: (1) it requires a continuous
intravenous infusion and multiple, timed urine collections; (2) inulin is
not easily available as a ready-to-inject solution for human use; (3) the
method is expensive, cumbersome and difficult to perform, due to
possible endogenous interferences. A single-injection of radiolabeled
[e.g., 51-labeled ethylenediaminetetraacetic acid (51Cr-EDTA) and
99mtechnetium diethylenetetraminepentaacetic acid (99mTc-DTPA)] and
non-isotopic (e.g. iohexol and iothalamate) tracers has been proposed
as an alternative tool for GFR measurement [3,4]. Even if these
methods are useful to determine renal function, a small amount of a
substance must be injected and several blood samples have to be per-
formed. For these reasons, creatinine-based estimated equations are
currently used for diagnosing chronic kidney disease, including Mod-
ification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equations. However in patients
with an orthotopic bladder substitution, a poor correlation has been
observed between estimated GFR (eGFR) and 51Cr-EDTA GFR [3]. This
is probably due to the resorptive function of the neobladder [5]. Factors
that may affect creatinine absorption include the segment of bowel
used, its surface area, mucus production, diuresis, duration of urine
retention and urinary creatinine concentrations [5,6]. As demonstrated
in animal models, reabsorption of urea and creatinine is more active in
ileal mucosa, which is used to construct the neobladder, as compared to
sigmoid mucosa [7]. On the other hand, exposing ileal mucosa to urine
reduces its absorptive capacity [6]. Multiple studies have described the
evolution of the mucosa in the neobladder during long term follow-up
with a decrease in absorptive capacity. This process of mucosal adap-
tation reaches a stable situation after one year [8–10]. Finally, low
creatinine concentrations have been detected in ileal conduit due to
creatinase, leading to an underestimation of GFR [11].
Recent evidence has suggested that cystatin C may be a valuable
marker for determining GFR in patients with an orthotopic urinary
diversion. In healthy subjects, the urinary concentration of cystatin C is
low because cystatin C is absorbed and degraded by the proximal tu-
bules. Therefore, the serum concentration of cystatin C can hardly be
affected even if urinary cystatin C is absorbed by the mucosa of the
neobladder [12].
In conclusion, interpretation of creatinine-based eGFR should be
carried out with caution in patients with a neobladder. Although data
are still scanty, cystatin C seems to be a practical and relatively af-
fordable surrogate marker for isotopic GFR in these patients.
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